Search
teclistamab-cqyv (Tecvayli)
Indications:
- relapsed/refractory multiple myeloma (FDA-approved) [2]
* overall response rate of 65% over a median follow-up of 6 months
Dosage:
- intravenous or subcutaneous administration
- 1500 ug/kg after 60 ug/kg & 300 ug/kg step-up doses
Adverse effects:
- treatment related adverse effects common (up to 80%)
- neutropenia (40%)
- anemia (28%)
- thrombocytopenia (20%)
- cytokine release syndrome (70%).
Mechanism of action:
- bispecific antibody
- binds B-cell maturation antigen (BCMA) & CD3 to redirect T cells to multiple myeloma cells
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
bispecific antibody; bispecific monoclonal antibody
References
- Bassett M
Bispecific Antibody Shows Promise in R/R Multiple Myeloma.
Investigational agent yielded responses in nearly two-thirds of patients
MedPage Today August 20, 2021
https://www.medpagetoday.com/hematologyoncology/myeloma/94157
- Usmani SZ, Garfall AL, van de Donk NWC
Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients
with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre,
open-label, single-arm, phase 1 study.
Lancet. 2021 Aug 10;S0140-6736(21)01338-6
PMID: 34388396
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01338-6/fulltext
- Bankhead C
FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamab.
Bispecific antibody achieved durable responses in a majority of heavily pretreated
patients.
MedPage Today October 25, 2022
https://www.medpagetoday.com/hematologyoncology/myeloma/101422